Alliance Revenue (Tables)

6 Months Ended

Jun. 30, 2018

Alliance Revenue

Schedule of accompanying statements of operations and comprehensive loss

	Three months ended				Six months ended
	June 30,				June 30,
(In thousands)	2018		2017		2018		2017
GSK collaboration (1)	$	141	$	186	$	283	$	557
Vivelix collaboration (2)		—		—		56		—
Other (3)		22		1		79		8
Total Alliance revenue	$	163	$	187	$	418	$	565

(1) For all periods presented, revenue recognized primarily relates to the amortization of the deferred up-front payment received at inception of the Company’s collaboration and license agreement with GSK Agreement, as more fully described in Note 8. Revenue recognized for the six months ended June 30, 2017 also includes an additional $0.1 million related to additional research services provided in connection with the collaboration and license agreement with GSK. 

(2) For the six months ended June 30, 2018, revenue recognized relates to services provided under the research program provided for under the Company’s exclusive license and collaboration agreement with Vivelix, as more fully described in Note 8.

Note 7.  Alliance Revenue (Continued)

(3) For all periods presented, revenue recognized relates to collaborations which are not material to the Company’s current operations nor expected to be material in the future, including reimbursements by licensees of costs associated with patent maintenance.

Schedule of changes in the Company’s contract assets and liabilities

	Six months ended June 30, 2018
(In thousands)	Beginning		Additions		Deductions		Ending
Contract assets	$	—	$	—	$	—	$	—
Contract liabilities:
Deferred revenue	$	566	$	—	$	(331)	$	235
	Six months ended June 30, 2017
(In thousands)	Beginning		Additions		Deductions		Ending
Contract assets	$	—	$	—	$	—	$	—
Contract liabilities:
Deferred revenue	$	1,263	$	—	$	(465)	$	798